Compare HFBL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFBL | ATNM |
|---|---|---|
| Founded | 1924 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 36.8M |
| IPO Year | 2010 | 2013 |
| Metric | HFBL | ATNM |
|---|---|---|
| Price | $19.57 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 2.0K | ★ 174.6K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | 7.69 | ★ 14.17 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $1,303,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ 17.49 | 11.11 |
| 52 Week Low | $12.32 | $0.95 |
| 52 Week High | $20.00 | $1.95 |
| Indicator | HFBL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 74.17 |
| Support Level | $15.77 | $1.39 |
| Resistance Level | $20.00 | $1.57 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 100.00 | 91.20 |
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.